RT Journal Article
T1 Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes
A1 Wolffenbuttel, B. H. R.
A1 Van Gaal, L.
A1 Duran-Garcia, S.
A1 Han, J.
K1 body mass index
K1 exenatide twice daily
K1 type 2 diabetes
K1 Peptide-1 receptor agonist
K1 Basal insulin
K1 Bolus insulin
K1 Safety
K1 Liraglutide
K1 Management
K1 Degludec
AB This post hoc analysis assessed the evidence behind common reimbursement practices by evaluating the relationship of body mass index (BMI) ranges (35 kg/m(2)) with treatment effects of exenatide twice daily among patients with type 2 diabetes. Patients received exenatide twice daily added to insulin glargine in two 30-week studies (exenatide twice daily vs insulin lispro, n = 627; exenatide twice daily vs placebo, n = 259). No association of baseline BMI with changes in efficacy variables was observed. Glycated haemoglobin (HbA1c) reductions were significant (p
PB Wiley
SN 1462-8902
YR 2016
FD 2016-08-01
LK http://hdl.handle.net/10668/18985
UL http://hdl.handle.net/10668/18985
LA en
DS RISalud
RD Apr 19, 2025